THIS WEBSITE USES cookies.
BY ACCESSING THIS WEBSITE, YOU EXPRESS YOUR CONSENT TO THE USE OF COOKIES IN ACCORDANCE
WITH THE TERMS OF THE Cookies Policy. IF YOU DO NOT CONSENT TO THE USE OF cookieS,
PLEASE ADJUST YOUR BROWSER SETTINGS ACCORDINGLY, OR DO NOT CONTINUE BROWSING THE SITE.

SEARCH:
  •   The Value
        of QUALITY
  •   Favouring
    SCIENTIFIC PROGRESS
  • The Value
    of RESEARCH
  • Research
    Tradition
  • Attention and
        Responsibility
    TOWARDS OF TERRITORY

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health.
sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs.
These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products.
Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.
In pursuit of its important mission of guaranteeing health and a better quality of life for people world-wide, sigma-tau has constantly combined economic expansion with the creation of value for society and the environment. Research, innovation and business must, in fact, be firmly linked to the social dimension - essential components of an entrepreneurial culture oriented towards responsible, sustainable development, fully respecting the needs of the individual, of society and of the environment.

 
 

25.04.2014
From: Financial Time

Public Private Partnerships Produce Affordable Treatments for Malaria
15.04.2013
From: Corriere Economia

Sigma Tau dopo la svolta torna l`utile
10.09.2012
From: www.20minutes.fr

Un traitment accessible en pharmacie

11.12.2013

L’AIFA introduce la nota 94 per i farmaci PUFA N‐3 (Esteri Etilici di acidi grassi polinsaturi della serie Omega-3). Tornano prescrivibili a carico del SSN per i pazienti con sindrome coronarica acuta.
18.06.2013

A NEW EFFICIENT AND COST EFFECTIVE DIALYSIS FOR PATIENTS WITH END STAGE RENAL DISEASE
03.06.2013

SIGMA-TAU RECEIVES INNOVATION AWARD FROM THE NATIONAL ORGANIZATION FOR RARE DISORDERS FOR ITS ADVANCEMENTS IN RARE DISEASES

 
 
 
 
2014© sigma-tau s.p.a. | VAT no. 00885531004